Comments
Drug maker Granules India today said US health regulator FDA has inspected its Gagillapur manufacturing facility near Hyderabad and did not find any deviation from good manufacturing norms.
“The United States Food and Drug Administration (USFDA) had inspected Gagillapur facility last week and the inspection concluded with no observations,” Granules India said in a filing to BSE.
The inspection was triggered by one of the applicant’s Abbreviated New Drug Application (ANDA) filing, it added.
The company manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages at its Gagillapur facility.
Shares of Granules India today closed at Rs 908.70 on BSE, up 3.43 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.